Suppr超能文献

抑制3-羟基-3-甲基戊二酰辅酶A(HMG CoA)还原酶可通过对膜磷脂酰丝氨酸的作用减弱因子VIIa/组织因子和凝血酶原酶的活性。

Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine.

作者信息

Dietzen Dennis J, Page Keith L, Tetzloff Tina A, Bohrer Alan, Turk John

机构信息

Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):690-6. doi: 10.1161/01.ATV.0000255949.51053.ce. Epub 2006 Dec 21.

Abstract

OBJECTIVE

3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) exhibit antithrombotic properties that are independent of reductions in circulating LDL cholesterol. We hypothesized that these antithrombotic properties are mediated by membrane alterations secondary to disrupted lipid metabolism.

METHODS AND RESULTS

EA.hy926 cells were incubated in the presence of 1 micromol/L atorvastatin supplemented with fetal bovine serum or lipid-depleted serum mixtures. Lipid restriction alone had no effect on cell lipid composition but when atorvastatin was included, phosphatidylserine, sphingomyelin, and cholesterol were reduced by 50% while ceramide content decreased by 70%. These changes in lipid composition did not alter the association of decay accelerating factor or tissue factor with lipid rafts. Atorvastatin in combination with lipid restriction reduced factor VIIa/tissue factor activity by as much as 75% but did not alter tissue factor expression. Prothrombinase activity was reduced to an extent similar to factor VIIa/tissue factor. Mevalonic acid but not LDL reversed the observed changes in lipid content and prothrombinase activity induced by atorvastatin. These findings were confirmed in primary cells.

CONCLUSIONS

Inhibition of HMG-CoA reductase limits exposure of phosphatidylserine at the cell surface by restricting the cellular pool of mevalonate-derived isoprenoids. This membrane alteration restricts the activity of proteolytic enzyme complexes that propagate the coagulation cascade.

摘要

目的

3-羟基-3-甲基戊二酰辅酶A(HMG CoA)还原酶抑制剂(他汀类药物)具有抗血栓形成特性,且该特性独立于循环低密度脂蛋白胆固醇的降低。我们推测这些抗血栓形成特性是由脂质代谢紊乱继发的膜改变介导的。

方法与结果

将EA.hy926细胞在含有1微摩尔/升阿托伐他汀的条件下培养,分别补充胎牛血清或脂质耗尽的血清混合物。单独的脂质限制对细胞脂质组成没有影响,但当加入阿托伐他汀时,磷脂酰丝氨酸、鞘磷脂和胆固醇减少了50%,而神经酰胺含量减少了70%。脂质组成的这些变化并未改变衰变加速因子或组织因子与脂筏的结合。阿托伐他汀与脂质限制联合使用可使因子VIIa/组织因子活性降低多达75%,但不改变组织因子表达。凝血酶原酶活性降低的程度与因子VIIa/组织因子相似。甲羟戊酸而非低密度脂蛋白可逆转阿托伐他汀诱导的脂质含量和凝血酶原酶活性的变化。这些发现已在原代细胞中得到证实。

结论

抑制HMG-CoA还原酶通过限制甲羟戊酸衍生的类异戊二烯的细胞池来限制磷脂酰丝氨酸在细胞表面的暴露。这种膜改变限制了传播凝血级联反应的蛋白水解酶复合物的活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验